Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses
International Journal of Molecular Sciences · 30.01.2026 · 27 (3) · 1391
DOI: 10.3390/ijms27031391 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.01.2026. Verfasst von Supriya Mahajan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Medical Sciences and Research, Sharda University, Greater Noida 201306, UP, India. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Interleukins, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is characterized by profound immune dysregulation where interleukins play a central role in determining disease severity and response to interventions. This review summarizes the role of interleukins in the immunopathogenesis of COVID-19, with particular emphasis on differences observed across major SARS-CoV-2 variants. Pro-inflammatory interleukins like IL-1β, IL-6, IL-2, IL-17 and IL-18 are critically involved in cytokine storm, hyperinflammation, and acute respiratory distress syndrome, whereas anti-inflammatory cytokines like IL-10 contribute to immune regulation and resolution of inflammation. Elevated levels of IL-1α, IL-1β, IL-4, IL-8, IL-9, IL-16, IL-18 have been documented in the Delta variant as compared with the Omicron variant, with IL-6 being the most frequent interleukin reported to be increased across all SARS-CoV-2 variants relative to the ancestral Wuhan strain. Elevated IL-2, IL-4, IL-6, and IL-10 levels have been associated with Omicron sub-variants. The review encompasses interleukin-based therapeutic strategies, where several IL-1 and IL-6 inhibitors were studied across clinical trials, but only tocilizumab has shown some promise against severe COVID-19. IL-2, IL-6, IL-15 and IL-21 levels were positively correlated with IgG and neutralizing antibody activity after vaccination with longevity of post-vaccination immunity being determined by IL-2 and IL-7.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, School of Medical Sciences and Research, Sharda University, Greater Noida 201306, UP, India.
- Numed Super Speciality Hospital, Greater Noida 201306, UP, India.
Zitieren
APA
Mahajan, S., Mahajan, S., & Gusain, A. (2026). Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses. International Journal of Molecular Sciences, 27(3), 1391. https://doi.org/10.3390/ijms27031391
Vancouver
Mahajan S, Mahajan S, Gusain A. Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses. International Journal of Molecular Sciences. 2026;27(3):1391. doi:10.3390/ijms27031391
BibTeX
@article{Mahajan2026,
author = {Mahajan, Supriya and Mahajan, Saurabh and Gusain, Akanksha},
title = {Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {3},
pages = {1391},
doi = {10.3390/ijms27031391}
}
EUVIMED